In recognition of the impact of Aggrenox on stroke management, Aggrenox received priority review, and was granted approval within days of Health Canada's 180-day approval deadline.
Stroke is the second most common cause of death worldwide.
In Canada, it is the fourth leading cause of death and the leading cause of adult neurological disability. There are approximately 40,000 - 50,000 new cases of stroke in Canada each year. Aggrenox can be obtained through retail pharmacies by prescription only. The capsules are taken twice daily, once in the morning and once in the evening, with or without food. The most common side effects reported by the Aggrenox group in ESPS-2 were mild and transient headaches.